Centro de Investigación Médica Aplicada-ko ikertzaileekin lankidetzan egindako argitalpenak (32)

2023

  1. Cardiac Fibrosis in heart failure: Focus on non-invasive diagnosis and emerging therapeutic strategies

    Molecular Aspects of Medicine, Vol. 93

  2. Prediction of Left Ventricular Reverse Remodeling and Outcomes by Circulating Collagen-Derived Peptides

    JACC: Heart Failure, Vol. 11, Núm. 1, pp. 58-72

2020

  1. Author Correction: MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure (Scientific Reports, (2017), 7, 1, (40696), 10.1038/srep40696)

    Scientific Reports

2017

  1. Hypertensive Heart Disease

    Encyclopedia of Cardiovascular Research and Medicine (Elsevier), pp. 517-526

  2. Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men

    Free Radical Research, Vol. 51, Núm. 4, pp. 389-396

  3. Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites

    Scientific Reports, Vol. 7

  4. MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure

    Scientific Reports, Vol. 7

  5. Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome

    Journal of Hypertension, Vol. 35, Núm. 4, pp. 853-861

2016

  1. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: Potential role of altered collagen metabolism

    Journal of Hypertension, Vol. 34, Núm. 1, pp. 130-138

  2. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure

    Journal of the American College of Cardiology, Vol. 67, Núm. 3, pp. 251-260

2015

  1. Circulating biomarkers of myocardial fibrosis: The need for a reappraisal

    Journal of the American College of Cardiology, Vol. 65, Núm. 22, pp. 2449-2456

2014

  1. Association of Phagocytic NADPH Oxidase Activity With Hypertensive Heart Disease: A Role for Cardiotrophin-1?

    Hypertension, Vol. 63, Núm. 3, pp. 468-474

  2. microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation

    Clinical Science, Vol. 126, Núm. 7, pp. 497-506

2013

  1. A synthetic peptide from transforming growth factor-β1 Type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats

    Antioxidants and Redox Signaling, Vol. 19, Núm. 14, pp. 1607-1618

  2. Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis

    Clinical Science, Vol. 125, Núm. 6, pp. 291-300

2011

  1. HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia

    Cardiovascular Research, Vol. 92, Núm. 2, pp. 247-255

2010

  1. Corrigendum to "Preliminary characterisation of the promoter of the human p22phox gene: Identification of a new polymorphism associated with hypertension" [FEBS Lett. 542 (2003) 27-31]

    FEBS Letters

2009

  1. Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients

    Journal of Hypertension, Vol. 27, Núm. 7, pp. 1420-1430

  2. Insulin-induced NADPH oxidase activation promotes proliferation and matrix metalloproteinase activation in monocytes/macrophages

    Free Radical Biology and Medicine, Vol. 46, Núm. 8, pp. 1058-1067

  3. The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: Potential implication in hypertension

    Clinical Science, Vol. 116, Núm. 3, pp. 233-240